# Dual role of Lyz2-positive myeloid cells in traumatic brain injury: acute anti-inflammatory effects vs. chronic neurological deterioration

**Authors:** Hua-Zheng Yan, Yi-Wan Fang, Shi-Yu Zhou, Jian-Xiong Gao, Ming-Ming Bian, Yao-Mei Xu, Lin Zhang, Nan Zhang, He-Zuo Lü

PMC · DOI: 10.3389/fncel.2025.1642410 · Frontiers in Cellular Neuroscience · 2025-10-07

## TL;DR

This study shows that reducing a specific type of immune cell early after brain injury reduces initial inflammation but worsens long-term recovery.

## Contribution

The study reveals a dual role of Lyz2-positive myeloid cells in TBI, showing acute anti-inflammatory effects but chronic neurological deterioration.

## Key findings

- Depletion of Lyz2-positive myeloid cells reduced pro-inflammatory markers and increased anti-inflammatory markers early after TBI.
- Chronic behavioral and histological outcomes worsened despite early anti-inflammatory effects.
- Early suppression of myeloid-driven inflammation correlates with impaired long-term recovery after TBI.

## Abstract

Neuroinflammation is a critical factor contributing to secondary brain injury following traumatic brain injury (TBI). This process engages diverse cell types within the central nervous system (CNS), including significant infiltration of myeloid lineage cells–primarily neutrophils and macrophages–during the acute and subacute phases of TBI. These myeloid-derived cells represent a major population that critically influences the development and progression of neuroinflammation. Microglia and peripherally infiltrating macrophages exhibit polarization phenotypes that play a pivotal role in modulating inflammatory changes. Due to their functional and phenotypic similarities, their distinct contributions to the inflammatory response in TBI remain a subject of considerable debate. Lysozyme 2 (Lyz2) is a well-established marker for myeloid lineage cells (including monocytes, macrophages, and neutrophils) in mice, allowing specific targeting and depletion of these cells to dissect their functional roles in TBI.

In the present study, we investigated the trend of inflammatory factors during the early stage of TBI using Lyz2-IRES-DTREGFP transgenic mice, which specifically target and deplete Lyz2-positive myeloid cells. Tissue samples for RT-qPCR and flow cytometry were harvested from the perilesional cortex (within a 2-mm radius of the impact site) and the underlying hippocampus.

Our findings revealed a considerable reduction in the expression of pro-inflammatory factors (e.g., IL-1β, iNOS, IL-6, IFN-γ) and an increase in the expression of anti-inflammatory factors (e.g., IL-4, IL-10, IL-13, Arg-1). Furthermore, we observed a shift in polarization phenotypes, characterized by a decreased proportion of M1 macrophages and an increased proportion of M2 macrophages. However, during the chronic phase, behavioral and histological analyses revealed worse outcomes. These findings demonstrate that targeted depletion of Lyz2-positive myeloid cells during acute TBI attenuates neuroinflammation. However, this early immunomodulatory shift correlates paradoxically with exacerbated chronic neurological deficits, suggesting that transient suppression of myeloid-driven inflammation may disrupt long-term reparative processes critical for functional recovery after TBI.

## Linked entities

- **Genes:** Lyz2 (lysozyme 2) [NCBI Gene 17105], IL1B (interleukin 1 beta) [NCBI Gene 3553], NOS2 (nitric oxide synthase 2) [NCBI Gene 4843], IL6 (interleukin 6) [NCBI Gene 3569], IFNG (interferon gamma) [NCBI Gene 3458], IL4 (interleukin 4) [NCBI Gene 3565], IL10 (interleukin 10) [NCBI Gene 3586], IL13 (interleukin 13) [NCBI Gene 3596], ARG1 (arginase 1) [NCBI Gene 383]
- **Diseases:** traumatic brain injury (MONDO:0858950)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Il4 (interleukin 4) [NCBI Gene 16189] {aka BSF-1, Il-4}, Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Lyz2 (lysozyme 2) [NCBI Gene 17105] {aka Lys, Lysm, Lyzf2, Lyzs, Lzm, Lzm-s1}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, Nos2 (nitric oxide synthase 2, inducible) [NCBI Gene 18126] {aka MAC-NOS, NOS-II, Nos-2, Nos2a, i-NOS, iNOS}, Arg1 (arginase, liver) [NCBI Gene 11846] {aka AI, Arg-1, PGIF}, Il13 (interleukin 13) [NCBI Gene 16163] {aka Il-13}
- **Diseases:** brain injury (MESH:D001930), Neuroinflammation (MESH:D000090862), neurological deterioration (MESH:D009422), inflammation (MESH:D007249), neurological deficits (MESH:D009461), TBI (MESH:D000070642)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12537771/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12537771/full.md

## References

55 references — full list in the complete paper: https://tomesphere.com/paper/PMC12537771/full.md

---
Source: https://tomesphere.com/paper/PMC12537771